Raf, That would be ironic to say the least. My approach would be to get Vascepa adopted by the military to very quickly determine if Vascepa should be provided for all active duty members of the military. (Wish we had some contacts.)
And another thought provoking topic: Dr. Bhatt has tweeted endlessly about COVID19. "Risk of death skyrockets when COVID-19 patients have both CVD and myocardial injury." WHY DOES HE FAIL TO MENTION VASCEPA POST COVID RECOVERY? Are Bhatt/Amarin runnning a RWE study right now? Did they tell Bhatt to not mention anything regarding this...
As I mentioned previously it is a crucial / important aspect: the current status - invalid MARINE patents - has (could be has) an affect on "MARINE countries". As Chine is a big one: it is important / relevant issue.
W/o knowledge of the approved (applied) indication in Chine … and (or) the "final" status of MARINE status … nobody could assign a (real) value to RoW.
e.g.: China … at lesast three / four possible value exist
(1) China / MARINE & patents are invalid (2) China / MARINE & patents are valid (3) China / REDUCE-IT & patents are invalid (4) China / REDUCE-IT & patents are valid
What is the real value w/o know the exact status ...